Wall Street analysts expect Eli Lilly (LLY) to post quarterly earnings of $6.71 per share in its upcoming report, which indicates a year-over-year increase of 6.3%. Revenues are expected to be $20.26 billion, up 30.2% from the year-ago quarter.
Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 2.3% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
That said, let's delve into the average estimates of some Lilly metrics that Wall Street analysts commonly model and monitor.
The average prediction of analysts places 'Revenue- Cyramza (Ramucirumab /IMC-1121B)- Total' at $216.64 million. The estimate points to a change of -14.6% from the year-ago quarter.
Based on the collective assessment of analysts, 'Revenue- Humulin' should arrive at $157.59 million. The estimate suggests a change of -10.1% year over year.
Analysts predict that the 'Revenue- Jardiance (Empagliflozin/BI 10773)- Total' will reach $698.79 million. The estimate suggests a change of +1.3% year over year.
The consensus among analysts is that 'Revenue- Immunology' will reach $1.39 billion. The estimate suggests a change of +10.5% year over year.
The collective assessment of analysts points to an estimated 'Revenue- Cyramza (Ramucirumab /IMC-1121B)- US' of $103.53 million. The estimate points to a change of -15% from the year-ago quarter.
Analysts' assessment points toward 'Revenue- International- Humulin' reaching $50.75 million. The estimate suggests a change of -4.3% year over year.
Analysts expect 'Revenue- Trulicity (Dulaglutide / GLP-1 Fc / LY2189265)- US' to come in at $543.67 million. The estimate indicates a change of -26.9% from the prior-year quarter.
Analysts forecast 'Revenue- Trulicity (Dulaglutide / GLP-1 Fc / LY2189265)- ROW' to reach $308.19 million. The estimate points to a change of -11.5% from the year-ago quarter.
The combined assessment of analysts suggests that 'Revenue- Jardiance (Empagliflozin/BI 10773)- US' will likely reach $391.76 million. The estimate indicates a change of +2.5% from the prior-year quarter.
According to the collective judgment of analysts, 'Revenue- Jardiance (Empagliflozin/BI 10773)- ROW' should come in at $307.03 million. The estimate suggests a change of -0.3% year over year.
It is projected by analysts that the 'Revenue- Taltz (Ixekizumab / LY2439821 / IL-17)- US' will reach $529.59 million. The estimate indicates a change of -3.5% from the prior-year quarter.
The consensus estimate for 'Revenue- Taltz (Ixekizumab / LY2439821 / IL-17)- ROW' stands at $315.98 million. The estimate points to a change of +5.8% from the year-ago quarter.
View all Key Company Metrics for Lilly here>>>Shares of Lilly have demonstrated returns of -4.9% over the past month compared to the Zacks S&P 500 composite's -0.5% change. With a Zacks Rank #3 (Hold), LLY is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Eli Lilly and Company (LLY): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).